Eikon Therapeutics (EIKN) KOL event summary

Introduction and agenda

• Discussion focused on PARP1 biology, unmet needs from first-gen PARP inhibitors, Eikon's PARP1 programs, and Werner helicase inhibitors.

• Agenda included updates on Eikon's clinical programs and strategic rationale for new therapies.

KOL background and credentials

• Dr. Tim Yap is a clinical trialist at MD Anderson, with extensive experience in synthetic lethality and PARP inhibitor development.

• Roger Perlmutter has led R&D at major pharma companies and now heads Eikon, focusing on innovative drug discovery using super-resolution microscopy.

Market insights and analysis

• First-gen PARP inhibitors target both PARP1 and PARP2, but PARP2 inhibition leads to hematologic toxicity, limiting dosing and duration.

• New PARP1-selective agents aim to improve tolerability and allow higher, more effective dosing.

• Approved PARP inhibitors are used in ovarian, breast, prostate, and pancreatic cancers, with complex label indications and combinations.

• Brain-penetrant PARP1 inhibitors could address unmet needs in breast cancer patients with CNS metastases.